About Adenylosuccinate synthetase isozyme 2
Adenylosuccinate synthetase isozyme 2 (ADSS2) is a protein
from Homo sapiens identified by UniProt accession
P30520, 456 residues long.
MolForge cross-references it against 0 known binders and
43 disease associations.
Target properties
| Protein name | Adenylosuccinate synthetase isozyme 2 |
| UniProt accession | P30520 |
| Gene | ADSS2 |
| Organism | Homo sapiens |
| Length | 456 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (43)
Diseases linked to this target (Open Targets).
- age at menopause · score 0.20
- mean corpuscular volume · score 0.11
- monocyte count · score 0.10
- myeloid white cell count · score 0.07
- self reported educational attainment · score 0.06
- monocyte percentage of leukocytes · score 0.06
- uterine fibroid · score 0.05
- cervical squamous intraepithelial neoplasia · score 0.05
- lymphocyte count · score 0.05
- mathematical ability · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P30520-F1 | alphafold | PREDICTED | 92.60 | — |
Amino-acid sequence (456 residues)
MAFAETYPAA SSLPNGDCGR PRARPGGNRV TVVLGAQWGD EGKGKVVDLL AQDADIVCRC QGGNNAGHTV VVDSVEYDFH LLPSGIINPN VTAFIGNGVV IHLPGLFEEA EKNVQKGKGL EGWEKRLIIS DRAHIVFDFH QAADGIQEQQ RQEQAGKNLG TTKKGIGPVY SSKAARSGLR MCDLVSDFDG FSERFKVLAN QYKSIYPTLE IDIEGELQKL KGYMEKIKPM VRDGVYFLYE ALHGPPKKIL VEGANAALLD IDFGTYPFVT SSNCTVGGVC TGLGMPPQNV GEVYGVVKAY TTRVGIGAFP TEQDNEIGEL LQTRGREFGV TTGRKRRCGW LDLVLLKYAH MINGFTALAL TKLDILDMFT EIKVGVAYKL DGEIIPHIPA NQEVLNKVEV QYKTLPGWNT DISNARAFKE LPVNAQNYVR FIEDELQIPV KWIGVGKSRE SMIQLF
Explore Adenylosuccinate synthetase isozyme 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets